CED Member Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer.
"Dave has provided meaningful contributions and leadership since joining Tranzyme," said Vipin Garg, Ph.D., president and CEO, in a statement on Tuesday. "I look forward to working with him in his new role as we continue to advance the Company," said Garg.
Mr. Moore joined Tranzyme in August 2011 from Johnson & Johnson as Vice President, Commercial Operations and his responsibilities were increased in January 2012 to include the oversight of Business Development.
In his new role as Chief Business Officer, Mr. Moore will be responsible for corporate development for the Company, including new discovery collaborations and advancing new opportunities for clinical stage assets, in addition to an increase in general management responsibilities.
Tranzyme Pharma recently transferred compounds to Bristol-Myers Squibb, a move that could be worth as much as $80 million.
Garg is a current member of the CED Board of Directors.